Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Onco Targets Ther
Hoofdauteurs: Donato, Eva M, Fernández-Zarzoso, Miguel, Hueso, Jose Antonio, de la Rubia, Javier
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2018
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6084082/
https://ncbi.nlm.nih.gov/pubmed/30122950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141053
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items